Updates

Kainos - Evolve document management software going gangbusters

April 2016

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Also on Budget day, Kainos issued its update. The business that is digitising various government services has seen a stronger H2 across several departments including the UK’s Ministry of Justice and Office of National Statistics.In healthcare, Evolve has seen new wins including InTouch Health, a leading provider of telehealth solutions, which has signed a five-year agreement to deploy Evolve to support applications in over 1,500 hospitals. Kainos is undertaking a phased transition from an up-front licence model for Evolve to a rental model based on annual licence fees. This allows the customer to treat the licence fee as an operational rather than capital expense. The benefits to Kainos in future are lower licence reven ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

EMIS

Paysafe - Shares move to new high following results

Kainos (October 2020)

Kainos -Huge beat on forecasts and special dividend (September 2020)

Kainos - Helping government deal with COVID-19 fallout (May 2020)

Kainos - Gain to date: 213% (December 2019)

Kainos - Headcount +26% to 1470 : best proxy for growth (June 2019)

Kainos - Employee number reaches 1,300 (January 2019)

Kainos (October 2018)

Kainos - All going well for government digitalisation (May 2018)

Kainos (January 2018)

Kainos (October 2017)

Kainos (July 2017)

Kainos (May 2017)

Kainos - Government digital side trading strongly (October 2016)

Kainos (July 2016)

Kainos - 88.7% of sales repeat in nature (May 2016)

Kainos - Order backlog +54% to Â£56.7m (December 2015)

Kainos (September 2015)

Kainos - 88% sales repeat in nature (August 2015)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X